Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Interest & Investment Income (2016 - 2023)

Rein Therapeutics filings provide 8 years of Interest & Investment Income readings, the most recent being $155000.0 for Q3 2023.

  • For the quarter ending Q3 2023, Interest & Investment Income rose 40.91% year-over-year to $155000.0, compared with a TTM value of $432000.0 through Sep 2023, up 114.93%, and an annual FY2019 reading of $587000.0, up 65.35% over the prior year.
  • Interest & Investment Income hit $155000.0 in Q3 2023 for Rein Therapeutics, up from $112000.0 in the prior quarter.
  • The five-year high for Interest & Investment Income was $207000.0 in Q2 2019, with the low at $5000.0 in Q3 2020.
  • Median Interest & Investment Income over the past 5 years was $58500.0 (2020), compared with a mean of $76125.0.
  • The sharpest move saw Interest & Investment Income tumbled 96.99% in 2020, then soared 423.81% in 2022.
  • Year by year, Interest & Investment Income stood at $112000.0 in 2019, then tumbled by 95.54% to $5000.0 in 2020, then soared by 320.0% to $21000.0 in 2021, then surged by 423.81% to $110000.0 in 2022, then soared by 40.91% to $155000.0 in 2023.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $155000.0, $112000.0, and $55000.0 for Q3 2023, Q2 2023, and Q1 2023 respectively.